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E-mail: cbollard@childrensnational.orgAdoptive T cell therapy has had dramatic successes in the treat-
ment of virus-related malignancies and infections following he-
matopoietic stem cell transplantation. We adapted this method
to produce ex vivo expanded HIV-specific T cells (HXTCs),
with the long-term goal of using HXTCs as part of strategies to
clear persistent HIV infection. In this phase 1 proof-of-concept
study (NCT02208167), we administered HXTCs to antiretrovi-
ral therapy (ART)-suppressed, HIV-infected participants. Par-
ticipants received two infusions of 2  107 cells/m2 HXTCs at
a 2-week interval. Leukapheresis was performed at baseline
and 12 weeks post-infusion to measure the frequency of resting
cell infection by the quantitative viral outgrowth assay (QVOA).
Overall, participants toleratedHXTCs,with only grade 1 adverse
events (AEs) related toHXTCs. Two of six participants exhibited
a detectable increase in CD8 T cell-mediated antiviral activity
following the two infusions in some, but not all, assays. As ex-
pected, however, in the absence of a latency reversing agent, no
meaningful decline in the frequency of resting CD4 T cell infec-
tion was detected. HXTC therapy in ART-suppressed, HIV-in-
fected individuals appears safe and well tolerated, without any
clinical signs of immune activation, likely due to the low residual
HIV antigen burden present during ART.
INTRODUCTION
HIV persists within a latent reservoir in transcriptionally quiescent
cells, unaffected by antiretroviral therapy (ART) and of limited visi-
bility to the immune system.1–3 The long half-life of these cells sug-
gests that more than 70 years of ART would be required to eradicate
this latent HIV reservoir.4,5 Approaches using pharmacological HIV
latency reversal agents (LRAs) to induce latent virus to express viral
protein may make this reservoir vulnerable to CD8 T cells and other
effector mechanisms.6–11
HIV-reactive CD8 T cells play a crucial role in the control of HIV
viremia.12–14 However, the existing HIV-specific immune responsein ART-suppressed individuals is insufficient to clear persistent infec-
tion, even in the presence of LRAs that induce HIV expression.15–17
Obstacles to immune-mediated clearance of reactivated latent HIV
include the low frequency of HIV-specific T cells in ART-suppressed
individuals, impaired CD4 T cell help, pre-existing immune escape
variants archived in the latent reservoir, and dysfunctional CD8
T cell function dominated by responses that lack specificity for these
escape variants.11,18–21
Adoptive T cell therapy using autologous T cells that are expanded
ex vivo in the presence of viral peptides and cytokines offers a safe
avenue for reeducation and expansion of T cell responses through pre-
cise manipulation of cell number, phenotype, and function that would
not otherwise be safe or feasible in vivo.22 Earlier adoptive T cell ther-
apy approaches for HIV had limited efficacy because of multiple fac-
tors, including use of single epitope specificity, the development of
escape variants in actively viremic participants, and effector cell
exhaustion following ex vivo expansion.22–27 Since these earlier at-
tempts, the adoptive T cell therapy field has made significant advances,
largely in the oncology field, that may be leveraged to overcome some
of the pitfalls encountered with earlier T cell therapy approaches for
HIV. Polyclonal, virus-specific T cells expanded ex vivo and reinfused
into hematopoietic stem cell transplant patients have shown efficacy
for the treatment of Epstein-Barr virus (EBV), cytomegalovirus
(CMV), adenovirus, BK virus, and human herpesvirus 6 infection28–34
as well as the treatment of EBV-mediated malignancies.35–39 T cells
Table 1. Clinical Characteristics and Baseline Reservoir Size
Study ID Age (Years) Sex Race/Ethnicity
Stage ART
Initiateda Nadir CD4 CD4 at Study Entry
Pre-ART
Viral Load Years on ART IUPMb
HXTC-02 50 M Caucasian chronic 168 563 323,000 8 0.21
HXTC-03 35 M Caucasian acute 427 721 24,905 7 <0.02
HXTC-04 65 M Caucasian acute 277 950 14,538,865 9.5 0.90
HXTC-05 53 M Caucasian chronic 174 1,047 635,000 2.5 2.49
HXTC-06 61 F African American chronic 528 943 18,910 1 0.24
HXTC-07 58 M Caucasian chronic 338 816 58,500 6 0.89
All values were taken at the time of screening or baseline leukapheresis.
aAcute HIV infection (AHI) was defined as: (1) a negative or indeterminate enzyme immunoassay (EIA) plus a reproducibly detectable HIV by amplification methods, or (2) a positive
fourth-generation HIV Ag/Ab combination assay and either a negative or indeterminate HIV rapid test or a negative/indeterminate western blot, or (3) a negative HIV RNA test within
45 days of a positive EIA and ART initiation. All others with confirmed HIV infection on ART were defined as having started HIV therapy during chronic infection.
bIUPM is infectious units per million, as measured by the quantitative outgrowth assay (QVOA) following maximal mitogenic stimulation with PHA as previously described.45generated using these sophisticated methods of expansion have been
safe and well tolerated, as well as highly effective.38,40
We previously demonstrated that it is feasible to adapt this method of
expansion of polyclonal virus-specific T cells to the HIV setting and
expand polyfunctional, potent HXTCs targeting multiple HIV epi-
topes under good manufacturing practice (GMP) conditions.41–43
In this study, we demonstrate the in vivo safety and tolerability of
HXTC therapy in HIV-infected, ART-suppressed participants.
RESULTS
Clinical Characteristics and Background of Participants
All participants were on a stable regimen of suppressive ART at the
time of study entry, with median duration of ART of 6.5 (range
1–9.5) years (Table 1). Participants were mostly male (five of the
six participants) and Caucasian (five of six participants), with one fe-
male African American participant, and had a median age of 55.5
(range 35–65) years (Table 1). Two of the six participants initiated
ART during acute infection.44 Nadir CD4 ranged from 168 to 528,
with a median of 277, although all participants had experienced
CD4 recovery following ART initiation. Reflecting the range in base-
line clinical and virologic characteristics, the frequency of persistent
resting CD4 T cell infection (“reservoir size”) in infected units per
million (IUPM) as measured by quantitative outgrowth assay
(QVOA45) ranged from below the limit of detection of the assay
(<0.02 per million in HXTC-03) to 2.49 per million, with a median
IUPM of 0.56, similar to those previously reported.4,11
HLA typing by sequencing was performed for all participants (Table
S1). One participant, HXTC-06, was found to have two HLA alleles
known to be favorable host factors, HLA-B*81:01 and HLA-
A*74:01.46–50 In contrast, HLA alleles associated with ineffective viral
control and rapid disease progression, HLA-B*18, HLA-B*35, and
HLA-B*08, were found in HXTC-02, -04, and -05, respectively.51,52
HXTC Product Phenotype and Specificity
HXTCs were generated as previously reported, using lymphocytes
stimulated by irradiated autologous dendritic cells pulsed with over-lapping HIVpeptides spanning the entire regions of Gag, Pol, and Nef
in the presence of supportive cytokines and then stimulated by pep-
mix-pulsed autologous phytohemagglutinin (PHA)-treated lympho-
blasts (Figure S1).41,42 All cultures were performed in the presence
of the antiretroviral agents indinavir and raltegravir.
Using this expansion method, HXTCs were readily expanded to
numbers sufficient for use in the clinical trial after just two rounds of
stimulation in just over 3 weeks (Figure 1A). The total fold expansion
starting with bulk lymphocytes ranged from approximately 2.5 logs
(HXTC-04) to greater than 3 logs expansion, in the cases of HXTC-
02 and HXTC-06. As previously published, expansion is exponential,
with a significant augmentation of expansion following the second
stimulation.41,42 HXTCs exhibited specificity for the Gag, Nef, and
Pol peptide pools asmeasuredusing interferon gamma (IFNg) ELISpot
assays, with negligible nonspecific activity (Figure 1B). The magnitude
and breadth ofHIV-specific T cell responses within theHXTCproduct
varied among participants. HXTCs from three of the six participants
showed T cell responses to all three peptide pools (HXTC-05, -06,
and -07), twoexhibitedT cell responses to twoof the threepeptidepools
(HXTC-02 to Nef and Pol, and HXTC-03 to Gag and Pol), while
HXTCs from one participant had a T cell response targeting Nef only
(HXTC-04). The median magnitude of T cell responses was 146.0,
237.9, 549.1, and 650.58 IFNg spot-forming centers (SFCs)/105 cells
to Gag, Pol, Nef, and combined peptide pools, respectively.
HXTCs were predominantly CD8 T cells (median 72%, range 39%–
88%), although natural killer (NK) cells expanded within the HXTCs
from some participants, with the largest proportion seen in HXTC-07
(21.8%) and HXTC-04 (36.1%; Figure 1C). As expected, there were no
residual dendritic cells or co-stimulatory K562 cells detected at the
end of the expansion period (Figure 1C). Despite the two rounds of
stimulation, HXTCs displayed detectable but low levels of immune
exhaustion markers (Figure 1D).
HXTCs also demonstrated potent cytotoxicity against autologous
target cells pulsed with Gag, Pol, and Nef peptide pools in 51Cr release
assays (Figure 1E). Cytotoxicity was HIV-specific, with negligible 51Cr
Figure 1. Characterization of HXTC Products
(A) HXTC products expanded to clinically relevant levels after
two stimulations (n = 6). (B) All HXTCproducts produced IFNg
in response to HIV Gag, Neg, Pol (GNP) pepmix stimulation,
as measured on ELISpot. (C) Product phenotying by flow to
show T cells (CD45+, CD3+), CD4 T cells (CD3+CD4+), CD8+
T cells (CD3+CD8+), NK cells (CD3CD56+CD16+),
natural killer T (NKT) cells (CD3+CD56+CD16+), monocytes
(CD45+CD14+), dendritic cells (CD3CD83+, HLADR+), and
K562 cells (CD45+CD562, CD16, CD56, CD32+,
CD83+). (D) HXTC products displayed minimal exhaustion on
CD3+ T cells. (E) 51Chromium cytotoxicity assay shows spe-
cific lysis of HXTC products against autologous PHA blast
target cells pulsed with no peptides or HIV peptides (gag, nef,
pol peptide pools) at an E:T ratio of 20:1. Each data point
represents the mean of three technical replicates. *p < 0.05
by Wilcoxon signed rank test.release seen when HXTCs were co-cultured with autologous target
cells that were not pulsed with any peptide (Figure 1E). Maximum
HIV-specific cytotoxicity ranged from approximately 8% specific lysis
(HXTC-04) to greater than 60% specific lysis (HXTC-02), with a me-
dian cytotoxicity of 24%, at an effector:target (E:T) ratio of 20:1 (Fig-
ure 1E). Little difference was seen at ratios as low as 5:1, except for
HXTC-04, which exhibited a lower maximum cytotoxicity than
HXTCs from other participants and did show a dose-dependent cyto-
toxicity, with 4% specific lysis at the lowest E:T ratio tested (5:1), up to
a maximum of 8% specific lysis at higher E:T ratios.
HXTC Expression of Homing Markers to Gut and Lymph Node
Tissues
Homingmarkers, including integrina4b7, L-selectin (CD62L), and the
chemokine receptor CXCR5, were examined to determine whether
HXTCs exhibited the potential to home to putative sites of persistent
HIV infection, including the B cell follicle and the gut. Memory
CD8+ T cells (live, dump channel, CD3+, CD4, CD8+, CD45RO+;
Figure 2A for gating strategy) from threeHXTCparticipants were eval-
uated, chosen based on cell availability. Integrin a4b7 was expressed ata range of frequencies on baseline peripheral blood
mononuclear cells (PBMCs; mean of 31.25% of
memory CD8 T cells, range 12.85%–51.2%), and
trended to an increase in frequency in HXTCs
(mean 78% of memory CD8 T cells, range 41.4%–
97.5%) (Figure 2B). CD62L and CXCR5 were ex-
pressed on a minority of peripheral blood memory
T cells (mean 21.1%, range 14.0%–31.3% CD62L+
CD8 memory T cells; mean 2.8%, range 1.2%–
4.2% CXCR5+ CD8 memory T cells), and expres-
sion either remained stable or trended to a decrease
on HXTCs compared with PBMCs (Figure 2B).
HXTC Infusion Was Safe and Well Tolerated
All six participants completed the study proto-
col consisting of two HXTC infusions (2 10e7/m2/dose) 2 weeks apart, without dose-limiting toxicity. Overall,
the cell infusions were safe and well tolerated. Two participants
(HXTC-02 and HXTC-07) had transient, self-limiting fevers and
myalgia of DAIDs toxicity grade 1 severity 1 day post-infusion
(HXTC-02) and 2months post-infusion (HXTC-07). One participant
(HXTC-07) also experienced a transient increase in viremia above the
40 copies/mL limit of detection 1 month following infusion, with a
peak detectable viral load of 80 copies/mL that resolved without inter-
vention within 60 days. No other treatment-related adverse events
occurred. Other adverse events recorded were not attributable to
the HXTC infusion. This included a transient increase in blood pres-
sure with the leukapheresis procedure in four of six participants, an
expected and well-described effect of the procedure, all at or below
grade 3.
Antiviral Activity as Measured by a VIA and Latency Clearance
Assay following HXTC Infusion
We next determined whether the antiviral activity of CD8 T cells
isolated from PBMCs of participants was altered following HXTC
infusion using a viral inhibition assay (VIA) in which autologous
Figure 2. Homing Markers of PBMCs and HXTCs
PBMCs and HXTCs from three participants chosen based on cell availability were thawed, rested overnight, and stained for the described cell surface markers. Gating
strategy is shown in (A). The % of live, CD8+ memory T cells for the indicated homing marker is shown for both PBMCs and HXTCs (B). Data points represent the mean of
technical duplicates.activated CD4 T cells are spinoculated with the lab-adapted, CCR5
tropic HIV-1 isolate JR-CSF and co-cultured with CD8 T cells at a
low E:T ratio of 1:10. A decrease in the p24 production measured in
supernatant 6 days later indicates inhibition of viral spread. CD8
T cell performance in this assay may reflect multiple antiviral func-
tions, including proliferation, cytokine production, and cytotoxicity,
and has been associated with parameters of in vivo viremic con-
trol.53 Baseline antiviral activity varied among participants and
ranged from modest reduction of p24 production, to 50% of that
seen in the absence of CD8 T cell addition, to no reduction
(Figure 3A).
Two participants (HXTC-02, HXTC-07) exhibited a mild to modest
and sustained improvement in antiviral activity, with a reduction in
the %p24 production in this assay seen as early as 1 week following
the first infusion (Figures 3A–3F). The improved ability to reduce
p24 production was maintained through the last time point
measured, 13 weeks following the first infusion (Figures 3A and
3F). However, no impact on antiviral activity was seen in the remain-
ing four participants (Figures 3B–3E); in aggregate across all six
participants, no significant improvement in antiviral activity was
observed following HXTC infusion.
To measure the antiviral activity in an assay with potentially more
clinical relevance for participants on ART, during which time HIV
antigen exposure is likely rare and at very low levels, we performed
latency clearance assays (LCAs).42,54,55 In this assay, autologous
resting CD4 T cells were exposed to vorinostat, a histone deacetylase
inhibitor under clinical investigation as a LRA,6,8,9,43,56,57 and then
co-cultured with CD8 T cells for a discrete 24-hr period. CD8
T cells are then depleted so that reductions in virus recovery are
attributed to the discrete co-culture period only, and allogeneic acti-
vated CD8-depleted PBMCs are added to amplify any residual rare
virus in replicate wells plated under limiting dilution conditions. In
two of the six participants, the frequency of latent virus infectionwas too low at baseline to perform this assay with the cells available.
The participant with the strongest improved CD8 performance in
the VIA (HXTC-02) also showed an improved activity of CD8
T cells in the LCA following HXTC infusion, from modest (50%)
reduction in virus recovery with co-culture with pre-infusion CD8
T cells to complete ablation of virus recovery with co-culture with
post-infusion CD8 T (p = 0.01 by Fisher’s exact test). Although a
trend toward reduction was seen for the other three participants,
it was not statistically significant due to the low number of positive
wells in the control condition (three or fewer positive wells in con-
trol condition). The total number of wells plated was restricted due
to limited cell availability and the large number of cells required for
the assay, a known limitation of the assay,43 preventing definitive
conclusions from being drawn. The week 13 post-infusion time
point evaluated was chosen based on cell availability from the leu-
kapheresis procedure; earlier post-infusion time points were not
assessed.
The Frequency of HIV-Specific T Cells as Measured by IFNg
Release Did Not Change following HXTC Infusion
The impact of HXTC infusion on ex vivo HIV-specific T cell
responses was measured by IFN-g ELISpot. HIV reactive T cell re-
sponses were detectable in all six participants at baseline. No increase
or change in T cell specificity was observed following HXTC infusion.
IFNg release from T cells in response to clade B consensus peptide
pools of Gag, Pol, or Nef was detectable for at least one of the three
peptide pools in all six participants at baseline, with a median of
61.5 SFU/105 PBMCs to Gag (Figure 4A), a median of 58.8
SFU/105 PBMCs to Pol (Figure 4B), and a median of 47.7 SFU/105
PBMCs to Nef (Figure 4C). Overall, despite the increase in antiviral
activity detected in two of the six participants, no significant change
in IFNg release to Gag, Nef, or Pol peptide pools was observed
when measured at 1, 2, 4, 8, and 13 weeks following the first HXTC
infusion (results shown for week 13).
Figure 3. Antiviral Activity following HXTC Infusion
(A–F) Viral inhibition assay against autologous activated CD4 T cells infected with JR-CSF and co-cultured with CD8 T cells at an effector:target ratio of 1:10 obtained from
participants at baseline (averaged from 4 and 0 weeks before infusion) and 1, 2, 3, and 13 weeks post-infusion. HXTC-02 (A), HXTC-03 (B), HXTC-04 (C), HXTC-05 (D),
HXTC-06 (E), HXTC-07 (F). Infusions occurred at weeks 0 and 2, denoted by arrows. Results are displayed as %p24 production, normalized to the p24 obtained in the
absence of any CD8 effector cells. Error bars represent SEM of n = 4 replicates per time point per participant. Arrows denote HXTC infusion. *p < 0.05 by one-way ANOVA
with Dunnett’s post-test correction for multiple comparisons.Virologic Outcome following HXTC Infusion
We next assayed the frequency of rare, latently infected resting CD4
T cells via the quantitative viral outgrowth assay (QVOA) using maxi-
mally activated resting CD4 T cells, as previously described.4 Overall,
no change in the frequency of latently infected resting CD4 T cells was
observed following HXTC infusion, indicating no detectable impact
on the latent reservoir (Figure 5A; p = 0.13 by Wilcoxon matched-
pairs signed rank test). To assess the effect of HXTC infusion on
persistent, residual low-level viremia, we measured the plasma load
of HIV using a single-copy assay (SCA) capable of detecting plasma
RNA levels lower than 1 copy/mL.58 Two baseline SCA values were
obtained prior to infusion; then plasma samples were analyzed at
weeks 3 and 13 following the first infusion. Five of six participants
had detectable low-level viremia at baseline, with a median of 2
copies/mL (range 0.74–5.5), consistent with what has been reported.59
No significant change in low-level, residual viremia was detected (Fig-
ure 5B; p = 0.58 by Friedman’s test). High variability of SCA results
for participants from visit to visit was observed and was consistent
with results from longitudinal studies of ART-suppressed individ-
uals.59 The high visit-to-visit variability would prevent detection of
more modest reductions.
DISCUSSION
HXTC infusions were safe and well tolerated in HIV-infected, ART-
suppressed individuals, with few mild treatment-related adverse
events (grade %1). The safety and tolerability in this first proof-of-
concept study for HXTC therapy is consistent with results of previousclinical trials of adoptively transferred virus-specific T cells, with most
studies documenting only grade 1 or 2 adverse events.40
Two of six participants demonstrated an increase in CD8 T cell anti-
viral activity against JR-CSF HIV-infected autologous targets in an
ex vivo autologous assay (VIA), although the clinical significance of
this mild to modest impact is unknown. Interestingly, these were
the participants who reported mild flu-like illnesses following infu-
sion. This increase in antiviral activity did not correlate with an in-
crease in the apparent frequency of HIV-specific T cells as measured
by IFNg release following stimulation with Gag, Pol, and Nef peptide
pools. This discrepancymay be explained by underlying differences in
the assays. IFNg release following overnight stimulation measures
only one aspect of antiviral function over a short time period. In
contrast, VIAs span 6 days of co-culture, and thus may reflect multi-
ple antiviral functions including proliferation, cytokine release, and
cytotoxicity. HXTC product of the participant with the strongest in-
crease in antiviral activity (HXTC-02) did exhibit by far the strongest
HIV-specific cytotoxicity. Importantly, antiviral activity as measured
in a VIA has been associated with in vivo parameters of viremic con-
trol;53 however, the robustness and utility of such assays in the setting
of efforts to clear persistent HIV infection require further study and
validation. Further evaluations into the mechanisms underlying this
difference in antiviral capacity, including the breadth of HIV-specific
responses and functional avidity of the TCRs, will be important to
include in analysis if this signal is replicated in larger numbers as
additional participants receive HXTC infusions in ongoing studies.
Figure 4. HIV-Specific T Cell Responses following HXTC Infusion by IFNg Release
PBMCs isolated from leukapheresis products were stimulated with overlapping peptides spanning HIV Clade B Gag (A), Pol (B), or Nef (C) overnight in an ELISpot assay.
Resulting IFNg spot-forming units per 1  105 PBMCs are displayed. Error bars represent SEM of n = 4 replicates.Because the majority of the HXTCs were composed of CD8 T cells,
CD8 T cells were the focus of analysis in this manuscript. However,
additional cell subsets were present in the HXTC product to varying
degrees, including NK cells, in particular in two of the participants.
This may be a reflection of the use of modified K562 cells during
the expansion process. Recent studies have shown that particular
NK cell phenotypes and functional signatures have been associated
with improved viremic control and lower reservoir sizes,60,61 and
that NK cells are capable of migrating into B cell follicles during sim-
ian immunodeficiency virus (SIV) infection,62 sparking interest in
how to best enhance and employ NK cells for HIV cure.11,62–64
Further investigation into characterizing the NK cells within the
product and post-infusion in future studies may bear interesting re-
sults to help inform these efforts.
We did not observe any overall enhancement of the magnitude of the
HIV-specific immune response, by IFNg release or by VIA, when
evaluating participants in aggregate. This is not unexpected given
the low dose (2  107 cells/m2 per infusion) of the two infusions
and the absence of in vivo stimulus for expansion of the cells,
including the lack of concomitant robust HIV antigen exposure, no
pre-infusion lymphodepletion with myeloablative therapy and condi-
tioning, and no additional cytokine support that would promote
in vivo expansion of the cells. Notably, in the EBV setting, increasing
the dose beyond the total dose of 4 107 cells/m2 as used in this HIV
study did not translate to an increase in efficacy. This suggests that
simply increasing the cell dose may not improve immunologic or clin-ical impact, and additional strategies to promote in vivo expansion
may be necessary.
The lack of genetic engineering of T cells allows for an attractive safety
profile. However, a limitation of this approach is the inability to pre-
cisely track the migration, proliferation, and survival of HXTCs
in vivo. Ex vivo-expanded EBV-specific cells expanded under similar
conditions were found to survive for over 4 years following infusion in
patients with lymphoma, suggesting that HXTC therapy could have
similar longevity.38 However, extrapolation of these findings from
the setting of EBV-mediated lymphoma or hematopoietic stem cell
transplant to that of HIV infection is uncertain.
Homing receptor expression on the HXTCs suggests the potential for
homing to the gut, due to the high expression of the integrin a4b7
that is increased beyond what was seen in memory CD8 T cells of
the corresponding PBMCs. Integrin a4b7 expression is known to
be increased by up to 2-fold following exposure to supraphysiologic
levels of interleukin-7 (IL-7; albeit largely in the naive subpopulation
of CD4 and CD8 T cells), as was used in this particular expansion pro-
tocol, which may explain the high levels of a4b7 expression.65 In
contrast, the lymph node homing marker L-selectin (CD62L), which
facilitates entry into the lymph node via the high endothelial ve-
nules,66 and the B cell follicle homing chemokine receptor CXCR5,
which allows T cells to migrate to B cell follicles within the lymph
node along a CXCL13 axis,67 showed a trend to modest downregula-
tion on HXTCs when compared with memory CD8 T cells in PBMC
Figure 5. Neither the Latent HIV Reservoir Nor Residual Viremia Decreased following HXTC Infusion
(Left) QVOA was performed to determine the frequency of latently infected resting CD4 T cells using fresh resting CD4 T cells obtained from the baseline week 0 (pre-infusion)
and week 13 (post-infusion). Results are presented as infectious units per million (IUPM) CD4 T cells. (Right) The number of copies of HIV-1 Gag RNA/mL of plasma is shown
at the indicated time points. Gray shaded symbols indicate that results were below the limit of detection of the assay (values imputed were the threshold values).counterparts. This is consistent with what was observed in a preclin-
ical evaluation of HXTCs.41 Although IL-15 has been shown to induce
CXCR5 expression68 and was included during the HXTC expansion,
it is possible the overall activating signals may have driven down
expression of CXCR5 and/or the IL-15 impact was only transient.
Future work could include approaches to durably increase CXCR5
expression on the HXTCs, including optimization of the IL-15 expo-
sure during the expansion process, among other strategies,69,70 to
improve targeting the B cell follicles, a putative site of persistent
HIV infection.71 It is worth noting, however, that although downre-
gulated, the expressions of CD62L and CXCR5 were present; what
proportion of the HXTCs homing to lymph nodes is ideal for cure
strategies is not yet clear.
As expected with this study design, we did not find any decrease in the
size of the latent reservoir, as measured by QVOA. Additionally, we
did not observe any significant change in low-level residual viremia
by SCA at weeks 3 and 13 following the first infusion. There is the pos-
sibility that a modest decline in this measure of persistent HIV infec-
tion was unmeasurable given the known visit-to-visit fluctuation in
SCA values.4,59 However, it is most likely that the lack of an impact
on reservoir size was due to the absence of therapies designed to per-
turb the latent reservoir and induce recognizable expression of HIV
antigen.
A critical question will be whether HXTC therapy in combination
with latency reversing agents can deplete the HIV reservoir to an
extent that is measurable by current gold standard assays of HIV la-
tency. A 6-fold reduction measured by the current QVOA assay
would hold relevance for HIV cure strategies.4 Preclinical in vitro
studies suggest HXTC with the latency reversing agent vorinostat
is a promising approach.42 A study of HXTC in combination with
vorinostat is currently undergoing evaluation in an ongoing clinical
trial (NCT03212989). Should antigen production following LRA
exposure prove to be insufficient to drive in vivo expansion of
HXTCs, future studies may also need to incorporate strategies
such as optimized lymphodepletion therapies or adjunctive cytokine
therapy.MATERIALS AND METHODS
Clinical Protocol
In this phase I single-site study, participants between the ages of 18
and 65 years with a documented history of HIV infection on suppres-
sive ART for at least 1 year were eligible. Participants initiating ther-
apy during either chronic HIV infection (CHI) or acute HIV infection
(AHI) were eligible. AHI was defined as: (1) a negative or indetermi-
nate enzyme immunoassay (EIA) plus a reproducibly detectable HIV
by amplificationmethods, or (2) a positive fourth-generation HIV an-
tigen/antibody (Ag/Ab) combination assay and either a negative/
indeterminate HIV rapid test or a negative/indeterminate western
blot, or (3) a negative HIV RNA test within 45 days of a positive
EIA and ART initiation.
Notably, the HIV definitions above are pertinent to the time of diag-
nosis and treatment initiation. Active co-infections, such as HBV and
HCV, and prior receipt of an HIV vaccine and/or immunotherapy
within the past 12 months excluded potential participants. Once
enrolled, all participants continued baseline ART, completed a base-
line leukapheresis procedure, and received two 2  107/m2 doses of
HXTC infusions 2 weeks apart. The study collected serial blood sam-
ples throughout to measure immune response by IFNg ELISpot and
VIA, and to measure HIV RNA by SCA. Post-infusion assessments,
based on the date of the first infusion, included a leukapheresis per-
formed at week 13 and safety evaluation visits through week 48.
The study was approved by the University of North Carolina, Baylor
College of Medicine, and Children’s National Medical Center Institu-
tional Biomedical Review Boards, and written informed consent was
obtained from each participant.
Generation of HXTCs
HXTCs were generated as previously described.42,72 In brief, mono-
cytes were isolated from PBMCs by plastic adherence. Dendritic
cells were generated using standard cytokine cocktails of IL-4,
IL-1b, tumor necrosis factor alpha (TNF-a; R&D Systems, Minne-
apolis, MN, USA), IL-6 (Cellgenix, Freiburg, Germany), gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF) (Sanofi,
Bridgewater, NJ, USA), and prostaglandin E1 (PGE-1) (Pfizer, New 
York, NY, USA). Non-adherent PBMCs were cryopreserved and 
thawed upon completion of dendritic cell maturation. PBMCs 
were stimulated with irradiated autologous dendritic cells pulsed 
with Gag, Pol, and Nef peptide pools in the presence of IL-7, 
IL-12 (R&D Systems), and IL-15 (Cellgenix) for the first stimula-
tion. Cells were then co-cultured with autologous PHA-treated 
blasts pulsed with Gag, Pol, and Nef peptide pools in the presence 
of IL-15 (Cellgenix) for second stimulation and IL-2 (Prometheus, 
San Diego, CA, USA) for the optional third stimulation. HIV pep-
tide pools comprised overlapping 15-mer peptides by 11 amino 
acids, providing coverage of Gag p24, Pol, and Nef across HIV-1 
clades (JPT Peptide Technologies, Acton, MA, USA). Irradiated 
K562 cells (kind gift of Cell Medica, UK) modified to overexpress 
the co-stimulatory molecules CD80, CD83, CD86, and 4-1BBL 
were used in the second stimulation and in the optional third stim-
ulation. Expansions were performed in the presence of indinavir 
and raltegravir (Merck, Kenilworth, NJ, USA) to prevent replication 
of HIV.
IFNg ELISpot Assays
Participant PBMCs, cryopreserved at the designated time points pre-
and post-infusion, or HXTCs as indicated, were thawed and rested 
overnight for 16–24 hr in RPMI 1640 with 10% fetal bovine serum 
(FBS) and 1% glutamine. Cells were then harvested, recounted, and 
plated at 4  105 cells/well in quadruplicate (PBMCs) or 1  105 in 
triplicate (HXTCs) and stimulated with either Gag, Pol, or Nef pep-
tide pools (NIH AIDS Reagent Repository, Bethesda, MD, USA) at 
a final concentration of 2 mg/mL for 18–20 hr. For each assay, at least 
four negative control wells (no peptide, ‘Mock,’ or actin, with HXTC 
evaluations) and two positive control wells (PHA at a final concentra-
tion of 10 mg/mL, for PBMC tests, and staphylococcal enterotoxin B 
(SEB) for HXTC evaluation; Sigma-Aldrich, St. Louis, MO, USA) 
were included. For PBMCs, a threshold of 4 Mock and greater 
than 5 SFU/105 was used to determine positive responses, as previ-
ously reported by others.14,43,73 For HXTCs, a threshold of 4 nega-
tive control, actin SFU, and greater than 50 SFU/105 was used to 
determine positive responses.
Flow Cytometric Analysis
HXTC clinical products were phenotyped with antibodies (Miltenyi 
Biotech, Germany) staining for CD3 PerCP Vio700 (BW264/56), 
CD4 phycoerythrin (PE) Vio770 (M-T321), CD8 allophycocyanin 
(APC) Vio700 (BW135/80), CD45 VioGreen (5B1), CD56 PE 
(REA196), CD16 PE (REA423), CD14 VioBlue (TUK4), CD83 
APC (HB15), human leukocyte antigen (HLA)-DR fluorescein iso-
thiocyanate (FITC) (AC122), CD32 FITC (2E1), PD-1-PE-Vio770 
(PD1.3.1.3), LAG-3-APC (REA351), and TIM-3-PE (F38-2E2), and 
run on a MACSQUANT Flow Cytometer (Miltenyi Biotech, Ger-
many). Homing receptor markers were performed with staining for 
CD3 BUV395 (SK7), CD4 BUV496 (SK3), and CD8 BUV805 (SK1) 
from BD Biosciences (San Jose, CA, USA); CXCR5 APC (MU5UBEE) 
from eBioscience (Waltham, MA, USA); and CD45RO af488 
(UCHL1), CCR7 BV605 (G043H7), CD62L BV421 (DREG-56),and Integrin-b7 PE (FIB27) from BioLegend (San Diego, CA,
USA). A live/dead exclusion marker (Zombie Aqua; BioLegend)
and staining for exclusion markers (CD16, 3G8, CD56, HCD56,
CD14, M5E2, gd, B1, CD19, HIB19-BV510; BioLegend) were also
employed. Samples were analyzed on a BD LSRFortessa Flow Cytom-
eter (BD Biosciences).
Samples were run in parallel with appropriately labeled isotype-
matched antibodies and FMOs for gating strategies. Data were
analyzed with FlowJo Software (FlowJo, Ashland, OR, USA).
51Chromium Cytotoxicity Assay
The cytolytic activity of HXTCs was assessed in 51Cr sodium chro-
mate (CCS) (51Cr)-release assays 10 days after the final stimulation.
Untreated autologous PHA blasts (negative control) or PHA blasts
pulsed with Gag, Nef, and Pol pepmixes (JPT) were labeled with
CCS for 1 hr at 37C, washed, and resuspended with HXTCs at E:T
ratios from 40:1 to 5:1 and incubated for 4–8 hr. Spontaneous lysis
was determined by measuring 51Cr release from target cells into the
supernatant using a MicroBeta2 gamma counter (Perkin Elmer, Wal-
tham, MA, USA) in the absence of effectors. Maximum lysis was
measured by addition of 1% Triton X-100 (Sigma-Aldrich) to target
cells during the 4- to 8-hr incubation. Specific lysis was calculated
as follows: Specific lysis % = (experimental release  spontaneous
release)/(maximum release  spontaneous release)  100.
VIA
PBMCs were isolated from participants by peripheral blood draws at
the indicated time points by Ficoll isolation. PBMCs were frozen and
batched to allow all time points from each participant to be run simul-
taneously. CD8 T cells were isolated from PBMCs by positive selec-
tion (EasySep human CD8 Selection Kit; STEMCELL, Cambridge,
MA, USA). CD8-depleted PBMCs were preactivated with 2 mg/mL
PHA (Remel, Lenexa, KS, USA) and 60 U/mL IL-2, and spinoculated
at 2,500 rpm for 90 min with JR-CSF at an MOI of 0.005. A total of
5  104 targets/well was plated in quadruplicate and co-cultured
with HXTCs (E:T ratio of 1:10), autologous unexpanded CD8
T cells ( E:T ratio of 1:10), or no effectors, in 0.2 mL of RPMI 1640
media supplemented with 10% FBS, 1% penicillin/streptomycin,
and 5 U/mL IL-2. Supernatant was assayed on day 6 by p24 ELISA
(ABL, Rockville, MD, USA). Results were calculated as %p24 produc-
tion, normalized to the p24 supernatant concentration in the condi-
tion with no effector cells [(concentration p24 in effector wells)/(con-
centration p24 in control well)*100].
LCA
The LCA was performed as previously described.42,54,55 In brief,
resting CD4 T cells were isolated from a leukapheresis product by
negative selection and exposed to vorinostat (VOR) (335n; gift of
Merck Research Laboratories, Kenilworth, NJ, USA) at a concentra-
tion of 5 million/mL in the presence of the antiretrovirals abacavir
(4 mM; gift of Glaxo SmithKline, Philadelphia, PA, USA) and raltegra-
vir (1 mM; gift of Merck Research Laboratories, Kenilworth, NJ, USA).
After 6 hr, cells were extensively washed, and CD8 T cells were added
at an E:T ratio of 1:10. Antiretrovirals were again added, and cells
were co-cultured at a concentration of 5 million resting CD4
T cells/mL. After 24 hr, cells were extensively washed and depleted
of CD8 T cells via three serial magnetic selections (STEMCELL Tech-
nologies, Vancouver, BC, Canada). Remaining CD4 T cells were
recounted, then plated in 16–48 replicate wells at 0.25–1 million
cells/well (depending on cell availability and reservoir size) and
cultured with allogeneic CD8-depleted PBMCs from anHIV-negative
donor to amplify any residual virus. The presence of HIVGag p24 an-
tigen was measured on day 15 and confirmed on day 19 for each well
by ELISA (ABL, Rockville, MD, USA). Each LCAwas performed at an
independent time point.
Quantitative Viral Outgrowth Assay
Lymphocytes were obtained by continuous-flow leukapheresis. Isola-
tion of resting CD4 T cells and recovery and quantification of repli-
cation-competent virus were performed as described previously.45
In brief, approximately 34–49 million resting CD4 T cells were plated
in replicate-limiting dilutions of 2.5 million (12–18 cultures in 6-well
plates), 0.5 million (6 cultures in 12-well plates), and 0.1 million
(6 cultures in 12-well plates) cells per well, activated with PHA
(Remel, Lenexa, KS, USA) and a 5-fold excess of allogeneic irradiated
PBMCs from a seronegative donor and 60 U/mL IL-2 for 24 hr. Cul-
tures were washed and co-cultivated with CD8-depleted PBMCs
collected from selected HIV-seronegative donors screened for
adequate CCR5 expression. Culture supernatants were harvested on
days 15 and 19, and assayed for virus production by HIV p24 antigen
capture ELISA (ABL, Rockville, MD, USA). Cultures were scored as
positive if p24 was detected at day 15 and was increased in concentra-
tion at day 19. The number of resting CD4 T cells in IUPM was esti-
mated by a maximum likelihood method.74,75
Statistical Analysis
Statistical comparisons between groups were analyzed using the Wil-
coxon signed rank test or Friedman’s test with posttest correction for
multiple comparisons when results were taken in aggregate across
participants. Significance for each individual participant was analyzed
using a Dunnett’s test with posttest correction for multiple compari-
sons (VIA) or Fisher’s exact test (LCA). p < 0.05 was considered
significant.
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